USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: HIGH THROUGHPUT GENOMICS, INC.
Address: 3430 E. Global Loop
TUCSON, AZ 85706-
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $4,295,654.00 12
SBIR Phase II $1,599,493.00 1

Award List:

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen Felder
Award Amount: $93,275.00

SCREENING ARRAYS TO MONITOR APOPTOSIS GENE EXPRESSION

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ralph R. Martel
Award Amount: $93,675.00
Abstract:
A quantitative high-throughput gene chip assay, based on nuclease protection, has been developed for drug discovery. The assay permits the expression levels of numerous genes to be measured simultaneously in individual samples. We will use this technology to develop an assay that can measure… More

ArrayPlate Drug Metabolism and Toxicity Profiling

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce E. Seligmann
Award Amount: $500,000.00
Abstract:
DESCRIPTION (provided by applicant): The ArrayPlate is a new microplate-based technology for measuring a profile of gene expression now being used for target validation, high throughput screening, and QSAR lead optimization. This Phase I grant proposes to demonstrate that the ArrayPlate,… More

Whole Genome qNPA Gene Expression Platform

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce E. Seligmann
Award Amount: $274,583.00
Abstract:
DESCRIPTION (provided by applicant): The identification of gene targets for drug discovery, including AIDS research and mental health, relies heavily on the use of high density array whole genome platforms. It is also true for the discovery of biomarker s for diagnostic assays. The quantitative… More

Microfluidic Multiplexed mRNA Biomarker Platform

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce E. Seligmann
Award Amount: $299,436.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this Phase I 2nd resubmitted proposal is to demonstrate the feasibility of establishing a screening assay and platform (SP-qNPA Microfluidic Screening Platform) that monitors host cell response to detec t exposure to, and provide diagnosis of… More

In Vitro Gene Expression Model Predicting Drug Induced Liver Disease

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce E. Seligmann
Award Amount: $451,831.00
Abstract:
DESCRIPTION (provided by applicant): Phospholipidosis (PLDosis) or lipid metabolism disorders are a factor in many drug induced liver diseases. Drug induced, dose-dependent, alterations in the expression of sets of genes, whether direct cause or effect, ca n provide a molecular signature of the… More

miRNA HD Array Platform

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce E. Seligmann
Award Amount: $775,229.00
Abstract:
DESCRIPTION (provided by applicant): This application is a first resubmission of a Phase I application. An area of special interest to NIAID for SBIR/STTR applications is Biomarkers of Host Immune Defense to Bioterrorism Pathogens . The use of microRNA's (miRNA) expressed in white blood cells as… More

Nuclease Probe Mediated Sequencing

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce E. Seligmann
Award Amount: $599,268.00
Abstract:
DESCRIPTION (provided by applicant): Sequencing is very powerful for identifying differences in genomic DNA that may regulate cell function and diseases, pre-dispose persons to certain diseases, or warn of adverse drug metabolism. It provides a basis for i dentifying differences in gene expression,… More

Not Available

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kirk Collamer
Award Amount: $149,371.00
Abstract:
This Phase I proposal will develop and validate assays to measure the metabolism of compounds  and their affect on liver cells using a multiplexed gene expression assay platform, the quantitative Nuclease  Protection Assay (qNAP¿) that can measure the expression of up to 100 mRNA… More

Not Available

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce Seligmann
Award Amount: $149,967.00
Abstract:
A molecular test using FFPE tissue from patients to distinguish basal-like breast cancer from other subtypes will be developed and confirmed. The test will be based on a commercial platform, the lysis-on ly quantitative Nuclease Protection Assay (qNPA 1M). Current gene expression signatures… More

Screening Test for HPV+ Head and Neck Cancer

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce E. Seligmann
Award Amount: $600,000.00
Abstract:
DESCRIPTION (provided by applicant): There is currently no good way to screen for early stages of head and neck cancers caused by high risk types of human papillomavirus. The objective of this proposal is to develop a screening assay for dental patients to detect HPV+ head and neck cancer ( HNC )… More

qBead Assessment of miRNA in Alzheimer's Disease

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce E. Seligmann – 520-547-2828
Award Amount: $309,019.00
Abstract:
DESCRIPTION (provided by applicant): miRNA biomarkers related to Alzheimer's disease (AD) that may be useful as a diagnostic tool or in elucidating the mechanisms of disease and discovery of novel therapeutics will be identified using a novel whole transcriptome qBead X-MAP-based assay (not… More

Nuclease Probe Mediated Sequencing

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Debrah M. Thompson – 520-547-2827
Award Amount: $1,599,493.00
Abstract:
This Phase II proposal will complete the development of an innovative sequencing platform (NPSeq) based on feasibility demonstrated in Phase I. This platform uses a nuclease protection assay combined with universal PCR to produce targeted sequencing libraries. The lysis-only protocol means there is… More